Drug Profile
NPT 001 - National Pharmaceutical Technologies
Alternative Names: NPT-001 - National Pharmaceutical TechnologiesLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Lomonosov Moscow State University; National Pharmaceutical Technologies
- Developer N. N. Blokhin Cancer Research Center; National Pharmaceutical Technologies
- Class Antineoplastics
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; NUAK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in Russia